Asthma & COPD

OPKO owns global rights to a heparin-derived oligosaccharide intended for therapeutic use in asthma and COPD (chronic obstructive pulmonary disease). It is expected to demonstrate decreased side effects and improved efficacy as compared to current medications.

Our initial studies, using sheep and mouse asthma models, have demonstrated successful anti-inflammatory and anti-allergic activity when administered orally or inhaled with inhalers or nebulizers. Human feasibility studies for asthma have also proven successful.